ES2118683T1 - Factor antisecretorio peptidico que regula cambios patologicos de permeabilidad. - Google Patents

Factor antisecretorio peptidico que regula cambios patologicos de permeabilidad.

Info

Publication number
ES2118683T1
ES2118683T1 ES96929619T ES96929619T ES2118683T1 ES 2118683 T1 ES2118683 T1 ES 2118683T1 ES 96929619 T ES96929619 T ES 96929619T ES 96929619 T ES96929619 T ES 96929619T ES 2118683 T1 ES2118683 T1 ES 2118683T1
Authority
ES
Spain
Prior art keywords
fragments
approvals
secretory
permeability
pathological changes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES96929619T
Other languages
English (en)
Other versions
ES2118683T3 (es
Inventor
Ivar Loennroth
Stefan Lange
Eva Johansson
Eva Jennische
Christina Loennroth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rural Patent Svenska AB
Original Assignee
Rural Patent Svenska AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rural Patent Svenska AB filed Critical Rural Patent Svenska AB
Publication of ES2118683T1 publication Critical patent/ES2118683T1/es
Application granted granted Critical
Publication of ES2118683T3 publication Critical patent/ES2118683T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/142—Amino acids; Derivatives thereof
    • A23K20/147—Polymeric derivatives, e.g. peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Polymers & Plastics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Animal Husbandry (AREA)
  • Pulmonology (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Food Science & Technology (AREA)

Abstract

SE DESCRIBE UNA NUEVA PROTEINA RECOMBINANTE DENOMINADA FACTOR ANTISECRETORIO (RAF) Y HOMOLOGOS Y FRAGMENTOS PEPTIDICOS DE ESTA. LA PROTEINA Y LOS HOMOLOGOS Y LOS FRAGMENTOS DE ESTA SON UTILES PARA NORMALIZAR EL TRANSPORTE PATOLOGICO DE FLUIDOS Y/O LAS REACCIONES INFLAMATORIAS EN ANIMALES INCLUYENDO EL HOMBRE. SE DESCRIBEN ANTICUERPOS FRENTE A AF U HOMOLOGOS O FRAGMENTOS DE LOS MISMOS. TAMBIEN SE DESCRIBEN ACIDOS NUCLEICOS QUE CODIFICAN LA PROTEINA O LOS HOMOLOGOS O LOS FRAGMENTOS DE LOS MISMOS, ASI COMO TAMBIEN VECTORES Y HUESPEDES QUE CONTIENEN LOS ACIDOS NUCLEICOS. LOS RAF Y LOS HOMOLOGOS Y LOS FRAGMENTOS DE LOS MISMOS PODRIAN USARSE PARA INMUNODETECCION, COMO ADITIVO EN LA ALIMENTACION DE ANIMALES EN CRECIMIENTO Y COMO ANTIDIARREICO Y EN FARMACOS CONTRA ENFERMEDADES QUE IMPLICAN LA EXISTENCIA DE EDEMA, DESHIDRATACION Y/O INFLAMACION.
ES96929619T 1995-08-24 1996-08-23 Peptidos del factor antisecretor que regulan las modificaciones patologicas de permeabilidad. Expired - Lifetime ES2118683T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9502936A SE508609C2 (sv) 1995-08-24 1995-08-24 Antisekretorisk faktor - dess aminosyrasekvens, nubleinsyrasekvens och användning
SE9502936 1995-08-24

Publications (2)

Publication Number Publication Date
ES2118683T1 true ES2118683T1 (es) 1998-10-01
ES2118683T3 ES2118683T3 (es) 2004-12-01

Family

ID=20399269

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96929619T Expired - Lifetime ES2118683T3 (es) 1995-08-24 1996-08-23 Peptidos del factor antisecretor que regulan las modificaciones patologicas de permeabilidad.

Country Status (29)

Country Link
US (2) US6344440B1 (es)
EP (1) EP0851876B1 (es)
JP (2) JP4040679B2 (es)
KR (1) KR100552947B1 (es)
CN (1) CN1171902C (es)
AT (1) ATE270305T1 (es)
AU (1) AU702589B2 (es)
BG (1) BG63209B1 (es)
BR (1) BR9610308A (es)
CA (1) CA2230111C (es)
CZ (1) CZ295444B6 (es)
DE (2) DE851876T1 (es)
DK (1) DK0851876T3 (es)
EA (1) EA001201B1 (es)
EE (1) EE04501B1 (es)
ES (1) ES2118683T3 (es)
HK (1) HK1018468A1 (es)
HU (1) HU224971B1 (es)
IL (1) IL123404A (es)
NO (1) NO320560B1 (es)
NZ (2) NZ316647A (es)
PL (1) PL188530B1 (es)
PT (1) PT851876E (es)
RO (1) RO120197B1 (es)
SE (1) SE508609C2 (es)
SI (1) SI0851876T1 (es)
SK (1) SK23698A3 (es)
TR (1) TR199800304T1 (es)
WO (1) WO1997008202A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE508609C2 (sv) * 1995-08-24 1998-10-19 Rural Patent Svenska Ab Antisekretorisk faktor - dess aminosyrasekvens, nubleinsyrasekvens och användning
SE9604251L (sv) * 1996-11-20 1997-12-22 Svenska Lantmaennen Riksfoerbu Födoämne som vid förtäring inducerar antisekretoriska proteiner
SE513496C2 (sv) * 1998-12-17 2000-09-18 Rural Patent Svenska Ab NASP-berikad äggula samt dess användning
WO2001005968A1 (en) * 1999-06-21 2001-01-25 Inkine Pharmaceutical Company, Inc. Angiocidin: a cys-ser-val-thr-cys-gly specific tumor cell adhesion receptor
GB0322645D0 (en) * 2003-09-26 2003-10-29 Melacure Therapeutics Ab Use of antisecretory factor peptides
BRPI0710959B8 (pt) * 2006-04-27 2021-05-25 Lantmaennen As Faktor Ab uso de uma proteína anti-secretória ou fragmentos da mesma para a fabricação de uma composição farmacêutica para a prevenção ou tratamento da hipertensão intra-ocular.
MX2008013777A (es) 2006-04-27 2009-02-03 Lantmaennen As Faktor Ab Usos medicos adicionales de la proteina antisecretora.
DK2040734T3 (da) 2006-04-27 2012-01-23 Lantmaannen As Faktor Ab Antisekretorisk protein til anvendelse til behandling af kompartmentsyndrom
WO2010093324A1 (en) * 2009-02-11 2010-08-19 Lantmännen As-Faktor Ab Use of antisecretory factors (af) for optimizing cellular uptake
WO2010065342A1 (en) 2008-11-25 2010-06-10 Temple University Angiocidin inhibition of tumor cell growth
WO2017009004A1 (en) 2015-07-10 2017-01-19 Lantmännen As-Faktor Ab Process for producing egg yolk with high content of af-16
JP6999638B2 (ja) * 2016-07-18 2022-01-18 ラントメネン・メディカル・アーベー 抗分泌性因子１７
WO2020002464A1 (en) 2018-06-28 2020-01-02 Lantmännen Medical Ab Antisecretory factor for use in treatment and/or prevention of acute respiratory failure
WO2020065089A2 (en) 2018-09-28 2020-04-02 Lantmännen Functional Foods Ab A consumable product comprising malted dehulled oat
CN112770644A (zh) * 2018-09-28 2021-05-07 兰特门内保健食品公司 包含麦芽化小麦的可消耗产品
JP2023518790A (ja) 2020-03-26 2023-05-08 ラントメネン・ファンクショナル・フーズ・アーベー 身体活動時の回復を促進するための麦芽穀類を含む消費可能な製品

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE508609C2 (sv) * 1995-08-24 1998-10-19 Rural Patent Svenska Ab Antisekretorisk faktor - dess aminosyrasekvens, nubleinsyrasekvens och användning

Also Published As

Publication number Publication date
PL188530B1 (pl) 2005-02-28
DK0851876T3 (da) 2004-10-25
CN1171902C (zh) 2004-10-20
HU224971B1 (en) 2006-04-28
JP4040679B2 (ja) 2008-01-30
WO1997008202A1 (en) 1997-03-06
IL123404A (en) 2005-07-25
HUP9900137A2 (hu) 1999-04-28
RO120197B1 (ro) 2005-10-28
HK1018468A1 (en) 1999-12-24
CZ52098A3 (cs) 1998-09-16
KR100552947B1 (ko) 2006-04-21
SK23698A3 (en) 1998-12-02
JP2008043331A (ja) 2008-02-28
ATE270305T1 (de) 2004-07-15
EA001201B1 (ru) 2000-12-25
NZ337380A (en) 2001-02-23
EA199800221A1 (ru) 1998-10-29
PL325114A1 (en) 1998-07-06
NZ316647A (en) 1999-10-28
BG63209B1 (bg) 2001-06-29
NO980743D0 (no) 1998-02-23
EP0851876B1 (en) 2004-06-30
JPH11511972A (ja) 1999-10-19
SI0851876T1 (en) 2004-10-31
AU6893296A (en) 1997-03-19
DE851876T1 (de) 1998-11-12
BR9610308A (pt) 1999-12-21
CA2230111A1 (en) 1997-03-06
EE9800055A (et) 1998-08-17
KR19990044110A (ko) 1999-06-25
AU702589B2 (en) 1999-02-25
US6344440B1 (en) 2002-02-05
CN1208420A (zh) 1999-02-17
BG102280A (en) 1999-04-30
ES2118683T3 (es) 2004-12-01
IL123404A0 (en) 1998-09-24
NO980743L (no) 1998-04-16
CA2230111C (en) 2012-10-30
US20020099016A1 (en) 2002-07-25
SE9502936L (sv) 1997-02-25
HUP9900137A3 (en) 1999-11-29
SE9502936D0 (sv) 1995-08-24
DE69632828T2 (de) 2005-07-14
EE04501B1 (et) 2005-06-15
SE508609C2 (sv) 1998-10-19
TR199800304T1 (xx) 1998-05-21
CZ295444B6 (cs) 2005-08-17
DE69632828D1 (de) 2004-08-05
NO320560B1 (no) 2005-12-19
EP0851876A1 (en) 1998-07-08
PT851876E (pt) 2004-10-29

Similar Documents

Publication Publication Date Title
ES2118683T1 (es) Factor antisecretorio peptidico que regula cambios patologicos de permeabilidad.
DK457587A (da) Fremgangsmaade til fremstilling af et protein af faktor viii:c-typen
UA49814C2 (uk) Композиція, яка містить антиген вірусу папіломи, спосіб лікування цервікального раку, спосіб лікування гострокінцевої кондиломи
ATE297982T1 (de) Immortalisierter fusionspartner von kaninchen
EA200000109A1 (ru) Химерный белок растворимого рецептора интерлейкина-6/лиганда, его аналоги и способы применения
ATE206435T1 (de) Toxoplasma gondii-antigene, ihre herstellung und ihre verwendung
FI861575A (fi) Foerfarande foer odling av nematoder i vaetskeformigt medium.
DE69514354D1 (de) Verfahren zur herstellung von verbesserten biologischen pestiziden
Venugopal et al. Vitellins and vitellogenins of Dysdercus koenigii (Heteroptera: Pyrrhocoridae)—identification, purification and temporal pattern
DE60307266D1 (de) Methoden für die identifizierung und die entwicklung von komponenten die mit potential abhängigen kalium kanalen der kv4 familie interagieren
DE3880122D1 (de) Verfahren zur solubilisierung von unloeslichem protein.
ATE51710T1 (de) Methode zur bestimmung von hormonen.
GR3026434T3 (en) An antibody to the carboxyl terminus peptide of rat somatotropin binding protein
KR890009417A (ko) 모노크로날 항체의 제조방법 및 그것의 이용방법
ATE111299T1 (de) Verfahren zur aktivierung der mobilität von weibchen oophager insekten.
ATE175422T1 (de) Schweineadipozytenantigene und ihre verwendung zur immunologischen kontrolle von fett
SE8201538L (sv) Nytt proteinisoleringsforfarande
Murugan et al. Haemolymph protein profiles during the gonadotrophic period of Gesonula punctifrons Stal.(Orthoptera: Insecta)
Lakshmanna Dead ends in migrations: emerging trends in demographic dynamics
TH18474A (th) ลำดับดีเอนเอที่มีรหัสสำหรับหน่วยรับ bmp
ATE58245T1 (de) Verfahren zur photometrischen bestimmung biologischer agglutinaten.
DE3990097T1 (de) Immunoassays unter verwendung monoklonaler antikoerper, die gegen natuerliche bindende proteine gerichtet sind
AR012938A1 (es) Metodo para producir una proteina codificada por una secuencia de adn, anticuerpo especifico para el polipeptido, metodo para aislar e identificar el polipeptido, metodo para rastrear e identificar ligandos.
UY26304A1 (es) "oligocuerpos policlonales y monoclonales (reactivos sintéticos tipo anticuerpo basados en oligonucleótido), y un método para producir oligocuerpos."